Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Multiple Sclerosis (MS): Triggers, Mechanisms, History and Repair

A neuroimmunology brief on how EBV molecular mimicry, HLA genetics and environmental factors converge to strip myelin, and where treatment stands.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • The subtitle says modern medicine 'stops and reverses the damage'. Nothing approved reverses myelin damage. Remyelination is an active research frontier, not a treatment you can get.
  • The BTK inhibitor row lists fenebrutinib as if it were available. As of late 2026 no BTK inhibitor is FDA-approved for MS: tolebrutinib received a Complete Response Letter from the FDA in December 2025 over severe liver injury, though the EU approved it in June 2026 for non-relapsing secondary progressive MS, and fenebrutinib is still under FDA review.
  • Metformin with clemastine is listed under reversing damage. The CCMR-Two trial (70 people, 6 months) did show a signal of myelin repair on a nerve-signal-speed measure, but found no improvement in vision or disability, and the researchers specifically warned people not to obtain these drugs outside a trial.
  • Saint Lidwina of Schiedam is described as the earliest written clinical account of MS. This is a retrospective guess made centuries later and is debated by historians, not established. The diary of Augustus d'Este is usually dated 1822 to 1846. Charcot named the disease in 1868, but Robert Carswell (1838) and Jean Cruveilhier (1841) had already illustrated the plaques.
  • The Yamnaya ancient-DNA finding is real, but the explanation that a hair-trigger immune system was a survival advantage against animal pathogens is a proposed interpretation, not a demonstrated fact.
  • The nutrition section overstates what is known. Vitamin D supplementation has been shown to reduce antibody levels to the EBV protein EBNA1 in MS; it has not been shown to 'suppress EBV reactivation' or to change the course of MS. Omega-3 trials in MS have largely been negative. Magnesium, zinc and alpha-lipoic acid have no established role. B12 deficiency genuinely can cause myelin damage that mimics MS, and is worth testing for.
  • The core biology, including demyelination, scarring, axonal loss, the EBV and EBNA1 mimicry with GlialCAM, and the role of HLA-DRB1*15:01, matches what we found in the research.

Download the PDF

All source documents